IDEXX Laboratories, Inc.

IDXX · Healthcare

$518.00
+0.95% today

What a holder would want to know before buying IDXX: where the price sits in its own history, how far it has fallen before and whether it recovered, and what the business behind it earns. All of it is arithmetic over free market data — no opinions, no recommendations.

Where the price sits
Low $504.70 · Sep 2026High $766.68 · Nov 2025

Today’s price is 3% above the lowest point of the past year and 32% below the highest.

Over the past year it was cheaper than today on 6% of days and more expensive on 94%. Over the last 10 years: cheaper on 74% of days.

11% below its average price of the last 200 trading days.

How bad does it get

Fell 20% or more 4 times in 10 years. The deepest fall was 54%; the longest took 4.2 years to get back to its peak. 3 of 4 have recovered so far.

It is in one now: 32% below the Nov 2025 peak.

Nov 2025
−34%not back yet
Aug 2021
−54%back in 4.2 years
Feb 2020
−37%back in 3 months
Aug 2018
−31%back in 9 months
What you own

IDEXX Laboratories, Inc. · Healthcare · Diagnostics & Research · a large company worth $40.81B

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It…

Is it making money?
2022
2023
2024
2025

revenue profit

Sales of $4.30B in 2025, with $1.06B of profit. Sales grew in 3 of the last 3 years.

Keeps about 25 cents of every dollar of sales as profit.

Is it healthy?
Cash
$196.93M
Debt
$1.10B
Free cash flow / yr
$909.37M

Would need about 1.2 years of free cash flow to repay all its debt.

Is it expensive?

You pay $36 for every $1 of last year’s profit, and $31 for every $1 of profit expected next year.

A high number means buyers expect growth; a low one means they expect little, or fear trouble. Large US companies have averaged roughly 15–20 over the decades.

Pays no dividend.

What others are doing

13 analysts: 8 say buy, 4 hold, 1 sell. Their average 12-month target is $701.33 (range $470.00–$805.00).

Insiders made 0 purchases and 1 sale in the last 6 months. Executives routinely sell shares they were paid in; buying with their own money is the rarer signal.

Free data from Yahoo Finance, refreshed daily. This is evidence about the business and its price history, not a recommendation.

Now try it without risking anything

Poshkan is paper trading: real prices, virtual money. Buy IDXX with $10,000 that isn’t real, set a stop before you enter, and find out what your idea would actually have done.

Data from Yahoo Finance, refreshed hourly. Nothing here is financial advice. Poshkan is a paper-trading simulator — all money, trades and returns are virtual.